Theravance Inc  

(Public, NASDAQ:THRX)   Watch this stock  
Find more results for THEODORE FORE�
11.78
-0.21 (-1.75%)
Jan 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.43 - 12.13
52 week 11.16 - 32.91
Open 11.98
Vol / Avg. 1.01M/985,731.00
Mkt cap 1.37B
P/E     -
Div/yield 0.25/8.49
EPS -0.98
Shares 115.37M
Beta 1.94
Inst. own 82%
Feb 4, 2015
Q4 2014 Theravance Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 18, 2014
Theravance Inc at Stifel Healthcare Conference
Nov 13, 2014
Theravance Inc at Credit Suisse Healthcare Conference
Oct 30, 2014
Q3 2014 Theravance Inc Earnings Call
Oct 30, 2014
Q3 2014 Theravance Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -2129.23% -3587.66%
Operating margin -955.16% -3549.03%
EBITD margin - -3376.63%
Return on average assets -14.72% -32.52%
Return on average equity - -75.17%
Employees 241 -
CDP Score - -

Address

901 GATEWAY BLVD
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-8086000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Theravance, Inc. is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The Company operates in a single segment, which is focused on the discovery, development and commercialization of small molecule medicines across different therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company�s key programs include: RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, "FF/VI"), ANORO ELLIPTA (umeclidinium bromide/vilanterol, "UMEC/VI") and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with Glaxo Group Limited (GSK), and Long-Acting Muscarinic Antagonist program. Manufacturing of RELVAR/BREO ELLIPTA (FF/VI) and ANORO ELLIPTA (UMEC/VI) and for the MABA program is handled by GSK.

Officers and directors

William H. Waltrip Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Eric D'Esparbes Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
George B. Abercrombie Senior Vice President - Corporate Partnerships, Commercial
Age: 59
Bio & Compensation  - Reuters
Jeffrey D. Jonker Senior Vice President - Corporate and Business Development
Bio & Compensation  - Reuters
Junning Lee Senior Vice President - Technical Operations
Bio & Compensation  - Reuters
Frank Pasqualone Senior Vice President - Operations
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President - Corporate Partnerships, Clinical and Medical Affairs
Bio & Compensation  - Reuters
Michael W. Aguiar President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Henrietta Holsman Fore Independent Director
Bio & Compensation  - Reuters
Catherine J. Friedman Independent Director
Bio & Compensation  - Reuters